Publications by authors named "D Wichterle"
Introduction: Atrial fibrillation (AF) can cause or aggravate heart failure (HF). Catheter ablation (CA) is an effective treatment for AF. This study focused on the feasibility and outcomes of emergent AF ablation performed during hospitalization for acute HF.
View Article and Find Full Text PDFAims: Catheter ablation is an effective treatment method for recurrent ventricular tachycardias (VTs). However, at least in part, procedural and clinical outcomes are limited by challenges in generating an adequate lesion size in the ventricular myocardium. We investigated procedural and clinical outcomes of VT ablation using a novel 'large-footprint' catheter that allows the creation of larger lesions either by radiofrequency (RF) or by pulsed field (PF) energy.
View Article and Find Full Text PDFArticle Synopsis
- Pulsed electric field (PEF) energy shows potential as an effective method for catheter ablation in atrial fibrillation (AF), but its impact on red blood cells (erythrocytes) is not well understood.
- A study involving 60 AF patients found that PEF ablation significantly increased levels of free hemoglobin, lactate dehydrogenase, and bilirubin, indicating intravascular hemolysis after the procedure.
- The results suggested that the extent of hemolysis correlates strongly with the number of PEF applications, with more than 74 applications being linked to significant damage to red blood cells.
Background: Short and rare episodes of atrial fibrillation (AF) are commonly detected using implanted devices (device-detected AF) in patients with prior stroke or transient ischemic attack (TIA). The effectiveness and safety of oral anticoagulation in patients with prior stroke or TIA and device-detected AF but with no ECG-documented AF is unclear.
Methods And Results: This prespecified analysis of the NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes) trial with post hoc elements assessed the effect of oral anticoagulation in patients with device-detected AF with and without a prior stroke or TIA in the randomized, double-blind, double-dummy NOAH-AFNET 6 trial.